Russia still relies heavily on foreign-made medicines, especially Western ones, even as Vladimir Putin has prioritised economic and industrial independence, according to RFI English. A Bloomberg survey using DSM data found that 56 percent of Russian medicine spending in the first eight months of this year went to imports.
At the start of the 2022 full-scale invasion of Ukraine, imported medicines were 57 percent of spending, so dependence has barely fallen in four years, RFI English reported. Western sanctions exempt medicines on humanitarian grounds. EU pharmaceutical exports to Russia have risen since the war began, even as European exports overall have dropped sharply.
Roche, Novartis, AstraZeneca and Sanofi reportedly remain among the major players in the Russian market. Bloomberg calculations from Russian statistics service data show generic pharmaceutical output rose 71 percent in the first eight months of 2026 versus the same period in 2021, according to RFI English.
Putin wants 80 percent of essential medicines produced locally by 2030, an ambitious goal given technological and financial limits, according to the report.



